Press Releases Archives - Page 2 of 8

Psyence Group Inc. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

Psyence Group2025-06-27T11:17:13+02:00June 27, 2025|Press Releases, Investor Information, Psychedelic News|

Pursuant to the Offering, the Company has raised gross proceeds of C$600,000 split into two tranches. Tranche 1 closed today, and the Company has issued an aggregate of 4,760,000 Common Shares at a price of C$0.10 per Common Share for gross proceeds of C$476,000. Tranche 2 is anticipated to close on or about July 4, 2025 for the remaining gross proceeds of C$124,000. The Offering was originally announced on June 18, 2025. The net proceeds of the Offering will be used for general working capital purposes.

Psyence Group Inc. Announces Offering of up C$600,000 Non-Brokered Private Placement of Common Shares

Psyence Group2025-06-19T15:34:16+02:00June 19, 2025|Press Releases, Investor Information, Psychedelic News|

Psyence Group Inc are pleased to announce an offering of a non-brokered private placement (the “Offering”) of up to 6,000,000 common shares of the Company (the “Common Shares”) at a price of C$0.10 per Common Share for gross proceeds of up to C$600,000. No finder’s fees or commissions will be payable in connection with the Offering.

Psyence Group Announces Share Consolidation

Psyence Group2025-06-05T10:10:21+02:00June 5, 2025|Press Releases, Investor Information, Psychedelic News|

Psyence Group Inc announces that the Company will be consolidating all of its issued and outstanding share capital (the “Common Shares”) on the basis of every fifteen (15) old Common Shares into one (1) new Common Share (the “Share Consolidation”), effective April 23, 2025 with a record date of April 23, 2025 (the “Record Date”).

Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein

Psyence Group2025-03-26T08:47:52+02:00March 26, 2025|Press Releases, Investor Information, Psychedelic News|

Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it has expanded its newly created Scientific Advisory Board (SAB) with the addition of Dr. Dan J. Stein, a recognized leader in the field of psychopharmacology.

Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

Psyence Group2025-03-11T14:24:44+02:00March 11, 2025|Press Releases, Investor Information, Psychedelic News|

Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop its newly created Scientific Advisory Board (SAB).

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Psyence Group2024-12-11T06:51:14+02:00December 7, 2024|Investor Information, Psychedelic News, Press Releases|

Psyence Group hereby announces that it has entered into an addendum to the previously announced debt-for-equity swap agreements (the "Debt Swap Agreements") with its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), pursuant to which Psyence Biomed has agreed to issue to the Company 337,750 Psyence Biomed common shares at a deemed price of US$3.88 per common share, in exchange for the discharging of the balance of Psyence Biomed's obligations due under the Debt Swap Agreements and a promissory note, dated January 25, 2024, issued by Psyence Biomed to the Company in connection with Psyence Biomed's listing of its common shares on the NASDAQ in January 2024.

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

Psyence Group2024-11-07T09:16:20+02:00November 7, 2024|Press Releases, Investor Information, Psychedelic News|

Per the terms of the Disposal, Psyence Biomed will issue to Psyence Group 2,000,000 shares of its common stock. PsyLabs is focused on the cultivation and production of psychedelic active pharmaceutical ingredients (APIs) and extracts for use in research, clinical trials and drug development.

Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs

Psyence Group2024-11-04T08:15:58+02:00November 4, 2024|Press Releases, Investor Information, Psychedelic News|

Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions. Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustment Disorder topline data in the second half of 2025

Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Psyence Group2024-10-29T13:56:49+02:00October 25, 2024|Press Releases, Investor Information, Psychedelic News|

Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions. Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustment Disorder topline data in the second half of 2025

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

Psyence Group2024-10-29T13:46:46+02:00October 14, 2024|Investor Information, Psychedelic News, Press Releases|

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones